The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine patch to that of a reference formulation following repeated applications
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
74
Unnamed facility
Gières, France
Maximum Plasma Concentration (Cmax)
Time frame: During the third application of each period,12 time points up to 24h after the application
Time to Maximum Concentration (Tmax)
Time frame: During the third application of each period,12 time points up to 24h after the application
Area under the plasma concentration-time curve (AUC)
Time frame: During the third application of each period, 12 time points up to 24h after the application
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.